

Information for Connecticut Prescribers Provided Pursuant to Connecticut H.B. 6669

Under Connecticut law, prescription drug manufacturers are required to disclose in writing to Connecticut prescribers the list price of marketed drugs when engaging in prescription drug marketing, promotion, or in the provision of information regarding a legend drug for human use. This disclosure provides the list price in the form of the wholesale acquisition cost (“WAC”) for the product(s) listed below.

Marketed Product	NDC No.	WAC*
LYNOZYFIC™ (linvoseltamab-gcpt) injection 5mg/2.5mL single dose vial	61755-0054-01	\$470.00
LYNOZYFIC™ (linvoseltamab-gcpt) injection 200mg/10mL single dose vial	61755-0056-01	\$18,800.00

* WAC is the manufacturer’s undiscounted list price for a drug to wholesalers as reported to third party drug pricing publishers. WAC does not represent actual transaction price and does not include prompt pay or other discounts, rebates, or reductions in price. Most patients do not pay WAC. The amount a patient pays for LYNOZYFIC™ will vary and largely depends on whether the patient has insurance, the type of insurance, whether their insurance provider considers the medication to be preferred or not preferred, and whether the patient has met their insurance deductible. To find out the exact cost of a prescription, a patient should contact their health insurance provider or preferred pharmacy.

Pricing as of 07/02/2025